Moderna (MRNA) Retained Earnings (2017 - 2026)

Moderna (MRNA) has 10 years of Retained Earnings data on file, last reported at $5.9 billion in Q1 2026.

• On a quarterly basis, Retained Earnings rose 498.78% year-over-year to $5.9 billion in Q1 2026; TTM through Mar 2026 was $5.9 billion, a 498.78% increase from a year earlier, with the FY2025 full-year figure at $7.2 billion, up 734.06% from the prior year.
• Retained Earnings for Q1 2026 stood at $5.9 billion, down from $7.2 billion in the prior quarter.
• Over the last five years, Retained Earnings for MRNA reached as high as $18.3 billion in Q4 2022 and fell as low as -$240.0 million in Q2 2022.
• Historically, Retained Earnings has averaged $4.6 billion across 5 years, with a median of $866.0 million in 2024.
• Across the five-year window, Retained Earnings plunged 18500.0% in 2022 and soared 3930.69% in 2024, its largest moves.
• Year by year, Retained Earnings stood at $18.3 billion in 2022, then plunged by 100.67% to -$123.0 million in 2023, then surged by 804.07% to $866.0 million in 2024, then surged by 734.06% to $7.2 billion in 2025, then fell by 18.59% to $5.9 billion in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were $5.9 billion in Q1 2026, $7.2 billion in Q4 2025, and $8.0 billion in Q3 2025.